Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 4Leukemia, Myeloid, Acute 2Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Leukemia, Prolymphocytic 1Leukemia, B-Cell 1

Interventions

venetoclax 27Cyclophosphamide 18Azacitidine 13fludarabine 12ibrutinib 10Busulfan 10fludarabine phosphate 9Rituximab 8Mycophenolic Acid 8Methotrexate 8Cytarabine 8Whole-Body Irradiation 7Peripheral Blood Stem Cell Transplantation 7Clofarabine 7Therapeutics 6Melphalan 6Antilymphocyte Serum 6obinutuzumab 5Tacrolimus 5Surveys and Questionnaires 5Stem Cell Transplantation 5Mesna 5Exercise 5Cyclosporine 5vosaroxin 4trametinib 4thymoglobulin 4ruxolitinib 4ponatinib 4Trimethoprim, Sulfamethoxazole Drug Combination 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × dinaciclib × Other hematologic neoplasm × Clear all
NCT03484520 2022-12-30

A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

AbbVie

Phase 1 Terminated
48 enrolled
Other hematologic neoplasm

Neoplasms, Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡